MASLD (formerly NAFLD) and its inflammatory subset MASH (formerly NASH) affect ~38% and ~5% of U.S. adults respectively. Until recently, there were no FDA-approved drugs for either. In March 2024 resmetirom (Rezdiffra) was approved for MASH. A second class has since arrived: the Wegovy (semaglutide 2.4 mg) injection now carries an FDA accelerated-approval indication for noncirrhotic MASH with moderate to advanced fibrosis (Wegovy label, revised June 2026).

What MASLD and MASH are

SYNERGY-NASH — tirzepatide phase 2 trial

Loomba et al. (NEJM 2024) randomized 190 adults with biopsy-confirmed MASH and stage F2–F3 fibrosis to tirzepatide 5/10/15 mg vs placebo for 52 weeks.

Endpoint at 52 weeks5 mg10 mg15 mgPlacebo
MASH resolution44%56%62%10%
Fibrosis improvement ≥1 stage55%51%51%30%
Body weight change−10.7%−13.3%−15.6%−0.8%

This is the strongest MASH resolution effect ever reported in a randomized trial. Phase 3 program is enrolling.

ESSENCE — semaglutide phase 3 trial

Semaglutide 2.4 mg in MASH with stage F2–F3 fibrosis. Part 1 results at 72 weeks showed MASH resolution in about 62% with semaglutide vs about 34% with placebo, and fibrosis improvement in about 37% vs 22%. These results supported Wegovy's accelerated approval for MASH; the outcomes part of the trial continues.

Why GLP-1 may work in MASH

Multiple mechanisms beyond weight loss alone: improved insulin sensitivity (reduces hepatic lipogenesis), reduced systemic and hepatic inflammation, possible direct GLP-1 receptor effects in liver. The hepatic effect appears larger than would be predicted from weight loss alone, consistent with direct mechanism.

How to assess if you might have MASH

What this means for compounded GLP-1 use

Use of compounded GLP-1 for off-label MASH-directed treatment is becoming more common in clinical practice, especially in patients with concurrent obesity and high FIB-4 scores. Considerations:

What to expect next

Tirzepatide has no MASH indication; its phase 3 program continues. People with fatty liver disease are not eligible for the Medicare GLP-1 Bridge, though a Part D plan might cover a GLP-1 for an approved indication. Patients currently being treated for MASLD/MASH should expect treatment options to expand.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.